GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

Hossein Noyan-Ashraf, Mohammad; Abdul Momen, M.; Ban, Kiwon; Sadi, Al-Muktafi; Zhou, Yu-Qing; M. Riazi, Ali; L. Baggio, Laurie; Mark Henkelman, R.; Husain, Mansoor; J. Drucker, Daniel

doi:10.2337/db08-1193

Public

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

Shared by NobleBlocks on Jan 16, 2009 • 12:00 AM UTC

Authors:

Mohammad Hossein Noyan-Ashraf

M. Abdul Momen

Kiwon Ban

Abstract

OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before isch...

Discussions